Dr. Abramson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Mgh Cancer Center, Yawkey 9A
Boston, MA 02114Phone+1 617-724-4000Fax+1 617-726-8330- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Icahn School of Medicine at Mount SinaiClass of 2000
Certifications & Licensure
MA State Medical License 2002 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
Clinical Trials
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
- Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Start of enrollment: 2008 Jun 01
- Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Start of enrollment: 2008 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
- Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.Ahn, I., Brander, D., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C., Armand, P., Ng, S., C...> ;Blood Advances. 2024 Feb 27
- Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.Nemec, R., Scherrer-Crosbie, M., Abramson, J., Redd, R., Gilman, H., Ho, T., Wu, J., Heemelaar, J., Neuberg, D., Hochberg, E., Barnes, J., Armand, P., Jacobsen, E., Ja...> ;Leukemia & Lymphoma. 2024 Feb 21
- Join now to see all
Abstracts/Posters
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial re...2019 ASCO Annual Meeting - 6/1/2019
- Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene mara...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
Transplant vs. CAR T in DLBCL: Not Always an Either/Or QuestionOctober 21st, 2022- Less Is More: Rituximab Retreatment Tops Maintenance for Follicular LymphomaDecember 16th, 2021
- Adding Venetoclax to DA-EPOCH-R Leads to Excess Deaths in Double-Hit LymphomaDecember 13th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
